Search clinical trials for: CP4071

Total 14 results

Herbert Irving Comprehensive Cancer Center
National Cancer Institute (NCI)

Unknown

CP4071 in Treating Patients With Locally Advanced or Metastatic Soft Tissue Sarcoma

Sarcoma

United States
Pinnacle Pharmaceuticals, Inc.

Completed

Safety and Efficacy of PP4001 for the Treatment of Symptoms Associated With Uncomplicated Urinary Tract Infection

Urinary Tract Infection

United States
CARsgen Therapeutics Co., Ltd.

Not yet recruiting

Anti-GPRC5D CAR-T Cells (CT071) in Participants With RRMM or RRpPCL

Multiple Myeloma | Primary Plasma Cell Leukemia
Curon Biopharmaceutical (Australia) Co Pty Ltd
Novotech (Australia) Pty Limited

Terminated

A Study of CN1 in Combination With CN401 in Adult Patients With Relapsed/Refractory Lymphoid Malignancies

Relapsed Lymphoid Malignancies | Refractory Lymphoid Malignancies

Australia
Finch Research and Development LLC.

Terminated

A Trial of CP101 for the Prevention of Recurrent CDI (PRISM4) (PRISM4)

Recurrent C. Difficile Infection

United States, Canada
Circassia Limited

Completed

Phase III Cat-PAD Follow-on Study

Cat Allergy
Finch Research and Development LLC.

Withdrawn

Efficacy, Safety, and Tolerability Study of Oral Full-Spectrum MicrobiotaTM (CP101) in Subjects With Autism Spectrum Disorder and Associated GI Symptoms (SPROUT) (SPROUT)

Autism Spectrum Disorder | Autism | ASD | FMT | Fecal Transplant | Autistic Thinking | Autistic Behavior | Fecal Microbiota Transplant | Finch | CP101 | SPROUT
Finch Research and Development LLC.

Completed

Efficacy, Safety, and Tolerability Study of Oral Full-Spectrum MicrobiotaTM (CP101) in Subjects With Recurrent C. Diff (PRISM3)

Clostridium Difficile Infection Recurrence

Canada, United States
Finch Research and Development LLC.
Medpace, Inc.

Completed

Open-Label Extension of CP101 Trials Evaluating Oral Full-Spectrum Microbiota™ (CP101) in Subjects With Recurrence of Clostridium Difficile Infection (PRISM-EXT)

Clostridium Difficile Infection | Recurrent Clostridium Difficile Infection | C. Diff | CDI | Recurrent C. Diff | rCDI | C. Difficile | Recurrent CDI | FMT | Fecal Microbiota | Fecal Transplant

United States, Canada
Tigenix S.A.U.

Completed

Efficacy and Safety of Adipose Stem Cells to Treat Complex Perianal Fistulas Not Associated to Crohn´s Disease (FATT1)

Anal Fistula

Spain, Germany, United Kingdom
Tigenix S.A.U.

Completed

Long-term Safety and Efficacy of Adipose-derived Stem Cells to Treat Complex Perianal Fistulas in Patients Participating in the FATT-1 Randomized Controlled Trial (LTE)

Complex Perianal Fistula

Spain
Ajay Wasan, MD, Msc
National Institute on Drug Abuse (NIDA); National Institutes of Health (NIH)

Active, not recruiting

Implementing TMC-CP01 Treatment Based on the Virtual Autonomic Neuromodulation Induced Systemic Healing System in Reducing Pain and Opioid Requirement in Subjects Suffering From Chronic Low Back Pain (VANISH)

Chronic Low-back Pain

United States
Tigenix S.A.U.

Terminated

Safety and Efficacy of Adipose-Derived Stem Cells to Treat Complex Perianal Fistulas Patients With Crohn's Disease (FATT)

Crohn Disease | Complex Perianal Fistula

Spain, Netherlands, Austria
Geropharm

Completed

Efficacy and Safety of GP40071 Compared to NovoRapid® Penfill® in Type 1 Diabetes Mellitus Patients

Diabetes | Diabetes Mellitus, Type 1

Russian Federation

Search clinical trials for: CP4071

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Congo, DR of

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations